100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Grant Revenue link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Share-Based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Share-Based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Revenue - Summary of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue (Details Textual) [Default] link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Grant Revenue (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Balance Sheet Details (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Debt (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Debt - Summary of Final Payment Due at Repayment (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Share-Based Compensation Expense (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Related Party Transactions - Equity-Method Investment (Details Textual) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Accounts receivable Increase (Decrease) in Accounts Receivable Plan Name Plan Name [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Revenues [Abstract] Revenue: Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Contra expense included in research and development expense Contra Expense Included In Research And Development Expense Contra expense included in research and development expense. Number of operating segment for research and development Number of Operating Segments Vinbiocare [Member] Vinbiocare [Member] Vinbiocare. September 2021 Lease Agreement [Member] September Two Thousand And Twenty One Lease Agreement [Member] September two thousand and twenty one lease agreement. COVID-19 Vaccine Development C O V I D Nineteen Vaccine Development [Member] COVID-19 vaccine development. Balance (in shares) Balance (in shares) Shares, Outstanding Other Noncash Income (Expense), Total Other non-cash expenses Other Noncash Income (Expense) Increase decrease operating lease, right of use asset. Increase Decrease Operating Lease, Right Of Use Asset Right-of-use assets Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Long-term Debt, Type Long-Term Debt, Type [Domain] Long-term Debt, Current Maturities, Total Current portion of long-term debt Long-Term Debt, Current Maturities 2024 (remainder of year) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac entered into Co-Development Agreement. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Product and Service Product and Service [Axis] Investment, Name Investment, Name [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Janssen [Member] Janssen [Member] Janssen. Stockholders' Equity Equity [Text Block] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment and contingencies. Revenue Revenue from Contract with Customer [Text Block] Sale of Stock Sale of Stock [Domain] Entity Central Index Key Entity Central Index Key Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Milestone payments Milestone Payments Milestone payments. Restricted Cash Inventory, Cash Flow Policy [Policy Text Block] Proceeds from debt Net increase in indebtedness Proceeds from Issuance of Debt Common stock, shares issued Issuance of Shares Common Stock, Shares, Issued, Total Purchase of common stock, shares Directors or Officers [Member] Directors or Officers [Member] Directors or Officers. Liquidity Liquidity Policy Policy [Text Block] Liquidity. Stock issued during period value under equity plan. Stock Issued During Period Value Under Equity Plan Issuance of common stock under equity plans Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expense and other assets Increase (Decrease) in Prepaid Expense and Other Assets Entity Address, State or Province Entity Address, State or Province Potential principal repayment of loan Potential Principal Repayments Of Debt Instrument Potential Principal Repayments Of Debt Instrument. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net loss before income taxes Clinical trial accruals Clinical Trial Accruals Current Clinical trial accruals current. Revenue recognized Deductions Contract with Customer, Liability, Revenue Recognized Deductions Debt instrument, collateral Debt Instrument, Collateral Cystic Fibrosis Foundation [Member] Cystic Fibrosis Foundation Therapeutics Inc [Member] Cystic Fibrosis Foundation Therapeutics, Inc. CSL Collaboration Agreement. CSL Collaboration Agreement [Member] CSL Collaboration Agreement [Member] Equity Method Investment, Nonconsolidated Investee Equity Method Investment, Nonconsolidated Investee [Domain] Cover [Abstract] Earnings Per Share, Basic, Total Earnings Per Share, Basic Basic Contract with Customer, Asset, after Allowance for Credit Loss, Total Contract with Customer, Asset, after Allowance for Credit Loss Accounts receivable, Balance Accounts receivable, Balance Lessee, operating leases, option to extend Lessee, Operating Lease, Option to Extend Grants received from japanese government. Grants Received From Japanese Government Financial grants received from the Japanese government Payments for matching funds for remaining budgeted costs Payments For Matching Funds For Remaining Budgeted Costs Payments for matching funds for remaining budgeted costs. Operating expenses: Operating Expenses [Abstract] Issuance of common stock related to acquired in-process research and development (in shares) Stock Issued During Period, Shares, Acquisitions Schedule of Cash and Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Share-based compensation expenses Share-based compensation expenses Share-Based Payment Arrangement, Expense Total Long-term debt Long-Term Debt February 2020 Lease Agreement [Member] February Two Thousand And Twenty Lease Agreement [Member] February two thousand and twenty lease agreement. Revenue. Revenue [Line Items] Revenue [Line Items] Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Plan Name Plan Name [Axis] Current assets: Assets, Current [Abstract] Common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Disbursement Due July 2020 [Member] Disbursement Period Three [Member] Disbursement period three. Product and Service Product and Service [Domain] Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Term Term of agreement Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] Research Collaboration and Exclusive License Agreement. Common stock, par value Common Stock, Par or Stated Value Per Share Employee Stock Option [Member] Contract with Customer, Liability, Total Deferred revenue Contract with Customer, Liability Deferred revenue, Balance Deferred revenue, Balance Biomedical Advanced Research and Development Authority. Biomedical Advanced Research and Development Authority [Member] BARDA [Member] Taxes Payable, Current, Total Taxes Payable, Current Income tax payable Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Statement of Cash Flows [Abstract] Total expense recognized period Expense Included In Research And Development Expense Expense included in research and development expense. Counterparty Name Counterparty Name [Axis] Thereafter Lessee Operating Lease Liability Payments Due After Year Four Lessee operating lease liability payments due after year four. Exercise of warrants for shares of common stock Class of Warrant or Right, Number of Securities Called by Warrants or Rights Balance Sheet Related Disclosures [Abstract] Common Stock [Member] Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Employee-related Liabilities, Current, Total Accrued compensation Employee-related Liabilities, Current Wells Fargo Credit Agreement [Member] Wells fargo credit agreement. Wells Fargo Credit Agreement [Member] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Computer and software [Member] Computer Equipment [Member] COVID vaccination age limit COVID Vaccination Age Limit COVID vaccination age limit. Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Maximum LUNAR-COVID 19 sales required for Loans forgivable Maximum Sales Required For Loans Forgivable Maximum sales required for loans forgivable . Loan and Security Agreement [Member] Loan And Security Agreement [Member] Loan and security agreement. Subsequent Event Type [Axis] Amendment Flag Amendment Flag Increase (Decrease) in Operating Lease Liability Lease liabilities Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Prepayment fee percentage Prepayment Fee Percentage Prepayment fee percentage. Operating Lease Liability Current Statement Of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] SOFR [Member] Net income (loss) Net loss Net loss Issuance of common stock upon exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Variable Rate [Domain] Research and Development [Member] Research and Development Expense [Member] Equity Component Equity Component [Domain] Statistical Measurement Statistical Measurement [Domain] General and Administrative Expense, Total General and administrative General and Administrative Expense Ultragenyx [Member] Ultragenyx [Member] Ultragenyx. Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Finance income, net Other Nonoperating Income (Expense), Total Other Nonoperating Income (Expense) Accrued interest added to principal debt balance Debt Instrument, Increase, Accrued Interest Office equipment and furniture [Member] Furniture and Fixtures [Member] Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Proceeds from Lines of Credit, Total Proceeds from Lines of Credit Amount drawn from Loan Additional payments upon meeting certain clinical milestones. Additional Payments upon Meeting Certain Clinical Milestones Additional payments upon meeting certain clinical milestones Deferred Revenue, Current, Total Deferred revenue Deferred Revenue, Current Proceeds from exercise of stock options Proceeds from Stock Options Exercised Contra expense remaining amount included in accrued expenses Contra Expense Remaining Amount Included In Accrued Expenses Contra expense remaining amount included in accrued expenses. Restricted cash Restricted Cash, Current Deferred Revenue, Noncurrent, Total Deferred revenue, net of current portion Deferred Revenue, Noncurrent Non-current restricted cash Non-current restricted cash Restricted Cash, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, shares outstanding Common Stock, Shares, Outstanding Line of Credit Facility, Current Borrowing Capacity Revolving credit line available October 2017 Lease Amendment [Member] October Two Thousand And Seventeen Lease Amendment [Member] October 2017 lease amendment. Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Summary of significant accounting policy. Entity Interactive Data Current Entity Interactive Data Current Western Alliance Bank [Member] Western Alliance Bank [Member] Western Alliance Bank. Disbursement Due April 2020 [Member] Disbursement Period Two [Member] Disbursement period two. Document Quarterly Report Document Quarterly Report Cash and cash equivalents, including restricted cash Cash and cash equivalents, including restricted cash and non-current restricted cash Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash, cash equivalents and restricted cash at beginning of the period Cash, cash equivalents and restricted cash at end of the period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Related Party Transactions Related Party Transactions Disclosure [Text Block] Statistical Measurement Statistical Measurement [Axis] COVID-19 Vaccine [Member] COVID-19 Vaccine [Member] COVID-19 vaccine. Other Collaboration Revenue [Member] Other [Member] Other. Operating lease costs Operating Lease, Cost Related Party Related and Nonrelated Parties [Domain] Schedule of Revenue Disaggregation of Revenue [Table Text Block] Remaining Payments of Operating Lease Liability Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Number of shares available Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Loss Contingency, Nature [Domain] Research and Development Expense, Policy [Policy Text Block] Research and Development Costs, Net Income Statement Location Statement of Income Location, Balance [Axis] Minimum yncur amount agreed under research plan. Minimum Incur Amount Agreed Under Research Plan Minimum incur amount under research plan 2021 Inducement Equity Incentive Plan [Member] Twenty Twenty One Inducement Equity Incentive Plan [Member] 2021 Inducement equity incentive plan. Eligible to receive development milestone payment Eligible to Receive Development Milestone Payment Eligible to Receive Development Milestone Payment Number of shares owned Investment Owned, Balance, Shares Total assets Assets Total grant revenue Grant revenue Grant revenue. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Standards Not Yet Adopted Entity Address, City or Town Entity Address, City or Town Income (Loss) from Equity Method Investments, Total Income (Loss) from Equity Method Investments Loss from equity-method investment Loss from equity-method investment Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Development milestones received advance payment. Development Milestones Received Advance Payment Development milestones received advance payment Schedule of Share-based Compensation Expenses Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Term loan Debt Instrument, Face Amount Long-term Debt [Member] Long-Term Debt [Member] Manufacturing and Supply of ARCT-154 Drug Product [Member] manufacturing and supply of ARCT-154 drug product. Pre-Launch Inventory Pre Launch Inventory Policy Policy [Text Block] Pre-launch inventory policy. Private Placement [Member] Share-Based Compensation Expense Share-Based Payment Arrangement [Text Block] Construction in progress [Member] Construction in Progress [Member] Share-based compensation number of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Grant [Member] Grant Revenue [Member] Fair Value Disclosures [Abstract] Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, Total Loan origination fee paid Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums Common stock issued, value Stock Issued During Period, Value, New Issues Upfront payment received Upfront Payment Received Upfront payment received. Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Current liabilities: Liabilities, Current [Abstract] Lease Contractual Term Lease Contractual Term [Axis] Document Type Document Type Title of 12(b) Security Title of 12(b) Security Revenue. Revenue [Table] Revenue [Table] Repayment of principal and interest on collateralized term loan Repayments Of Principal And Interest On Collateralized Term Loan Repayments of principal and interest on collateralized term loan. Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Statement of Stockholders' Equity [Abstract] ADAIR Technology [Member] A D A I R Technology [Member] ADAIR Technology. Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense, Total Research and development, net Research and Development Expense Long-Term Debt, Excluding Current Maturities, Total Long-Term Debt, Excluding Current Maturities Long-term debt February 2021 Lease Agreement [Member] February Two Thousand And Twenty One Lease Agreement [Member] February two thousand and twenty one lease agreement. Contra research and development expense recognized Contra Research And Development Expense Contra research and development expense. Research Collaboration And License Agreement [Member] Research collaboration and license agreement. Research Collaboration And License Agreement [Member] Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Property and equipment, gross Property, Plant and Equipment, Gross Subsequent Event Type [Domain] Contract with customer liability additions. Contract With Customer Liability Additions Additions Leases Lessee, Leases [Policy Text Block] Tenant improvement allowance Payments for (Proceeds from) Tenant Allowance Keith C. Kummerfeld [Member] Keith C. Kummerfeld. Debt instrument, collateral amount Debt Instrument, Collateral Amount Collateral amount Share price Class of Warrant or Right, Exercise Price of Warrants or Rights Sale of Stock Sale of Stock [Axis] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Revenue from Contract with Customer, Excluding Assessed Tax, Total Total revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Statement of Comprehensive Income [Abstract] Income Taxes Income Tax Disclosure [Text Block] Grant 1 Grant One [Member] Grant one. Vinbiocare contractual liabilities Vinbiocare Contractual Liabilities Vinbiocare contractual liabilities. Depreciation and amortization expenses Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and stockholders’ equity Liabilities and Equity [Abstract] CureVac [Member] Cure Vac A G [Member] CureVac AG. Document Period End Date Document Period End Date Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Alexion [Member] Alexion Pharmaceuticals Inc [Member] Alexion Pharmaceuticals, Inc. Stockholders' Equity Note [Abstract] Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Grant Revenue Outstanding Grant revenue outstanding. Grant revenue outstanding APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Share-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Equity method ownership percentage Equity Method Investment, Ownership Percentage Total Accrued liabilities Accrued Liabilities, Current Income Tax Expense (Benefit), Total Income Tax Expense (Benefit) Provision for income taxes Income tax expense Trading Symbol Trading Symbol Vallon Pharmaceuticals, Inc. [Member] Vallon Pharmaceuticals Inc [Member] Vallon Pharmaceuticals, Inc. Variable Rate [Axis] Total stockholders’ equity Balance Balance Equity, Attributable to Parent Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Other non-current liabilities Other Liabilities, Noncurrent Sale of Stock, Number of Shares Issued in Transaction Equity method investment, sale of common stock Related Party Transactions [Abstract] Warrant fee payable Warrant Fee Payable Warrant fee payable. Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Minimum amount agreed to incur under research plan. Minimum Amount Agreed to Incur Under Research Plan Minimum amount agreed to incur under research plan Monthly base rent Monthly Base Rent Monthly base rent. Percentage of owned shares Investment Owned, Net Assets, Percentage Security deposit Security Deposit Geographical Geographical [Axis] Leases [Abstract] Research equipment [Member] Equipment [Member] Other accrued research and development expenses Other Accrued Research And Development Expenses Other accrued research and development expenses. Grant Revenue [Abstract] Grant Revenue Abstract. Proceeds from Issuance of Long-term Debt, Total Proceeds from long-term debt agreement Proceeds from Issuance of Long-Term Debt Class Of Stock [Line Items] Class of Stock [Line Items] Percentage required to be maintain in consolidated, unrestricted cash Percentage Required To Be Maintained In Consolidated Unrestricted Cash Percentage required to be maintained in consolidated unrestricted cash. Scenario Scenario [Axis] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Summary of Changes in Balances of Receivables and Contract Liability Security Exchange Name Security Exchange Name Counterparty Name Counterparty Name [Domain] Total operating expenses Operating Expenses Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Loss Contingency Nature [Axis] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Fair Value Measurements Fair Value Disclosures [Text Block] Interest Expense, Long-term Debt, Total Interest expense related to long-term debt Interest Expense, Long-Term Debt Disbursement Due October 2020 [Member] Disbursement Period Four [Member] Disbursement period four. 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Subsequent Event Subsequent Event [Member] Maximum [Member] Maximum [Member] Total liabilities and stockholders’ equity Liabilities and Equity Gain (Loss) on Extinguishment of Debt, Total Gain (Loss) on Extinguishment of Debt Gain on debt extinguishment Gain on debt extinguishment Operating Lease, Right-of-Use Asset Operating lease right-of-use assets, net Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Prime Rate [Member] Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Diluted Biomedical advanced research and development authority contract member. Biomedical Advanced Research And Development Authority Contract [Member] The BARDA Contract [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Contract with customer asset additions. Contract With Customer Asset Additions Additions Dividends, Total Dividends declared or paid Dividends Total liabilities Liabilities Debt instrument option for renewal term. Debt Instrument Option for Renewal Term Option for renewal term Term loan draw down Borrowings under Guaranteed Investment Agreements Development milestones achieved Development Milestones Achieved Development milestones achieved. Total current assets Assets, Current Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Issuance of common stock Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Grant Revenue Grant Revenue Disclosure [Text Block] The entire disclosure for grant revenue. Entity Filer Category Entity Filer Category Remaining loan including accrued interest forgiveable. Remaining Loan Including Accrued Interest Forgiveable Remaining loan including accrued interest forgiveable Property, Plant and Equipment [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Payments for advance Payments for Advance to Affiliate Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-based Payment Arrangement, Noncash Expense, Total Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Net profits percentage Percentage Of Net Profits Percentage of net profits. Vinbiocare Agreement [Member] Vinbiocare Agreement [Member] Vinbiocare agreement. Related Party Related and Nonrelated Parties [Axis] Lance Kurata [Member] Lance Kurata. Debt Instrument, Fee Amount Fee payable Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Singapore Economic Development Board [Member] SINGAPORE Entity Registrant Name Entity Registrant Name Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Loan maturity date Debt Instrument, Maturity Date Entity Emerging Growth Company Entity Emerging Growth Company Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Basic LUNAR-CF [Member] L U N A R C F [Member] LUNAR-CF. Common stock, shares authorized Common Stock, Shares Authorized Reduction in number of common stock shares available for future issuance Reduction in Number of Common Stock Capital Shares Available for Future Issuance Reduction in number of common stock capital shares available for future issuance. Equity Method Investment, Nonconsolidated Investee Equity Method Investment, Nonconsolidated Investee [Axis] Debt Disclosure [Abstract] Net Loss per Share Earnings Per Share, Policy [Policy Text Block] General and Administrative [Member] General and Administrative Expense [Member] Revenue Recognition Revenue [Policy Text Block] Phase I clinical study. Phase I Clinical Study [Member] Share-Based Payment Arrangement [Abstract] 2019 Omnibus Equity Incentive Plan [Member] Two Thousand Nineteen Omnibus Incentive Plan [Member] Two thousand nineteen omnibus incentive plan. Property Leases in San Diego [Member] Property Lease Guarantee [Member] Eligible to receive commercial milestone payment Eligible to Receive Commercial Milestone Payment Eligible to receive commercial milestone payment. Issuance of common stock related to acquired in-process research and development Stock Issued During Period, Value, Acquisitions Israel ministry of health. Israel Ministry of Health [Member] Israel Ministry of Health [Member] Accounting Policies [Abstract] Income Tax Disclosure [Abstract] Stockholders’ equity Equity, Attributable to Parent [Abstract] Non-cash investing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Statement [Table] Statement [Table] Segment Information Segment Reporting, Policy [Policy Text Block] Summary of Components of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Study Support Agreement Study Support Agreement [Member] Study support agreement. Entity File Number Securities Act File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash, cash equivalents and restricted cash Revenue from Contract with Customer [Abstract] Earnings Per Share [Abstract] Net loss per share: 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Lease Contractual Term Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Operating Income (Loss) Loss from operations 2023 Long-Term Debt, Maturity, Year One Entity Shell Company Entity Shell Company Loan accrued interest rate per annum, percentage Debt Instrument, Interest Rate, Effective Percentage Borrowings interest rate, percentage Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Deductions Contract with customer asset deductions. Contract With Customer Asset Deductions Deductions Entity Current Reporting Status Entity Current Reporting Status Line of Credit Facility, Interest Rate During Period Loans interest rate, percentage Long-term Debt, Type Long-Term Debt, Type [Axis] Subsequent Events [Abstract] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Geographical Geographical [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Received first installment Payment Received First Installment Payment received first installment. Repayments of Long-Term Debt, Total Repayments of Long-Term Debt Repayment of term loan Purchase of property and equipment in accounts payable Capital Expenditures Incurred but Not yet Paid City Area Code City Area Code Total current liabilities Liabilities, Current Final payment of disbursement amount Final Payment Of Disbursement Amount Final payment of disbursement amount. CSL seqirus. CSL Seqirus [Member] CSL Seqirus [Member] Local Phone Number Local Phone Number Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment and contingencies. Impairment loss Operating Lease, Impairment Loss Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional paid-in capital Additional Paid in Capital Grant awarded Grants Receivable mRNA Technology [Member] M R N A Technology [Member] mRNA technology. Commitments and Contingencies Disclosure [Abstract] Current portion of operating lease liability Operating Lease, Liability, Current Accumulated Deficit [Member] Retained Earnings [Member] Payments to Acquire Property, Plant, and Equipment, Total Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Accrued Liabilities, Current [Abstract] Document Transition Report Document Transition Report Loan first principal payment extended maturity date Debt Instrument, Date of First Required Payment 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Schedule of summary of significant accounting policies. Proceeds from the issuance of common stock under equity plans Proceeds from Stock Plans Prepaid expenses and other current assets Prepaid Expenses And Other Receivables The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable. Minimum [Member] Minimum [Member] Common Stock [Member] Common Stock [Member] Restricted cash Restricted Cash Restricted Cash, Total Investment, Name Investment, Name [Axis] Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Business acquisition of holding share. Business Acquisition Of Holding Share Business acquisition of holding share Collaboration revenue. Collaboration Revenue [Member] Collaboration Revenue [Member] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Income Statement Location Statement of Income Location, Balance [Domain] 2025 Lessee Operating Lease Liability Payments Due Next Twelve Months, Total Lessee, Operating Lease, Liability, to be Paid, Year One Royalty payment percentage of proceeds from net sales Royalty Payment Percentage Royalty payment percentage. Disbursed amount upon execution of amendment Disbursed Amount Upon Execution Of Amendment Disbursed amount upon execution of amendment. Foreign currency transaction loss Realized Gain (Loss), Foreign Currency Transaction, before Tax Underlying Agreement [Member] Underlying Agreement [Member] Underlying agreement. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Loan interest-only payment extended maturity date Debt Instrument Interest Only Payment Extended Maturity Date Debt instrument interest only payment extended maturity date. Non-cash asset disposal Non - Cash Asset Disposal Non-Cash Asset Disposal Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Joint Ventures, Equity Method Investments and Variable Interest Entities Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block] Joint ventures, equity method investments and variable interest entities. Scenario Scenario [Domain] Stock issued during period shares under equity plan. Stock Issued During Period Shares Under Equity Plan Issuance of common stock under equity plans (in shares) Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,084 at September 30, 2024 and 26,828 at December 31, 2023 Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common Stock, Value, Issued Debt instrument, extended term period. Debt Instrument, Extended Term Period Extended term period Operating Lease, Liability, Total Total operating lease liabilities Operating Lease, Liability Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Disbursement payment upon achievement of required manufacturing practices and IND application Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application Disbursement payment upon achievement of required manufacturing practices and IND application. Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Diluted Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Operating lease extended additional term Lessee, Operating Lease, Renewal Term Total remaining lease payments Lessee, Operating Lease, Liability, to be Paid Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average shares outstanding: Entity Small Business Entity Small Business Interest of the prime rate plus Debt Instrument, Basis Spread on Variable Rate Debt Debt Disclosure [Text Block] Seqirus Inc [Member] Seqirus, Inc [Member] Seqirus, Inc [Member] Seqirus, Inc. Payments on debt obligations Repayments of Debt Foreign Currency Transaction Gain (Loss), before Tax, Total Gain (Loss), Foreign Currency Transaction, before Tax Foreign currency transaction gain (loss) (Loss) gain from foreign currency Acquisition of in-process research and development through issuance of common stock Acquisition Of Research And Development In Process Through Issuance Of Common Stock Acquisition of research and development in process through issuance of common stock. Grant, number of installments Grant Receivable Number Of Installments Grant receivable number of installments. Disbursement Due January 2020 [Member] Disbursement Period One [Member] Disbursement period one. Disbursement amount payable upon achievement of project goal Disbursement Amount Payable Upon Achievement Of Project Goal Disbursement amount payable upon achievement of project goal. Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Grant 2 Grant Two [Member] Grant two. Extension to interest only period Debt Instrument Interest Only Payment Extended Period Debt instrument interest only payment extended period. Right-of-use assets acquired through operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Line of Credit Facility, Commitment Fee Percentage Non-refundable commitment fee, percentage Cystic Fibrosis Foundation liability Accrued cystic fibrosis foundation liability. Accrued Cystic Fibrosis Foundation Liability Cystic Fibrosis Foundation Liability (Note 9) Other Collaboration Agreements [Member] Other Collaboration Agreements [Member] Other collaboration agreements. Weighted-average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Subsequent Events Subsequent Events [Text Block] Accounts Payable, Current, Total Accounts payable Accounts Payable, Current GRI Bio Inc. GRI Bio Inc Member GRI Bio [Member] Increase (Decrease) in Accrued Liabilities, Total Accrued liabilities Increase (Decrease) in Accrued Liabilities